The Treatment of Bioartificial Liver With hiHep Cells After Extensive Hepatectomy

Recruiting Early Phase 1 Interventional Study
Hepatoma Resectable
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
30 – 80
Sex
Any
Trial phase
Early Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
10 (estimated)
Sponsor
Sir Run Run Shaw Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
It is a prospective, non-randomized, single-arm cohort study. A total of 10 patients will be included in this study. Based on standardized treatment, the treatment of bioartificial liver device will be applied 48-72 hours after extensive hepatectomy. The bioartificial liver device consists of clinical-grade human-induced hepatocytes (hiHep) generated from human fibroblasts via transdifferentiation…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Diagnosed as liver cancer, hepatolithiasis, benign liver tumor, with clear indications for liver resection; 2. Liver function Child A-B; 3. There is no contraindication to surgery for cardiopulmonary function; 4. The expected remaining liver volume/standard liver volume is le…
Contacts

Xiujun Cai, MD

0086-0571-86006605

caixiujunzju@yahoo.com.cn

CONTACT